Show simple item record

dc.contributor.authorJullien, Jeromeen
dc.contributor.authorAstrand, Carolinaen
dc.contributor.authorSzenker, Emmanuelleen
dc.contributor.authorGarrett, Nigelen
dc.contributor.authorAlmouzni, Genevieveen
dc.contributor.authorGurdon, Johnen
dc.date.accessioned2013-01-07T16:09:17Z
dc.date.available2013-01-07T16:09:17Z
dc.date.issued2012-10-29en
dc.identifier.issn1756-8935
dc.identifier.urihttp://www.dspace.cam.ac.uk/handle/1810/244103
dc.description.abstractAbstract Background Nuclear reprogramming is potentially important as a route to cell replacement and drug discovery, but little is known about its mechanism. Nuclear transfer to eggs and oocytes attempts to identify the mechanism of this direct route towards reprogramming by natural components. Here we analyze how the reprogramming of nuclei transplanted to Xenopus oocytes exploits the incorporation of the histone variant H3.3. Results After nuclear transplantation, oocyte-derived H3.3 but not H3.2, is deposited on several regions of the genome including rDNA, major satellite repeats, and the regulatory regions of Oct4. This major H3.3 deposition occurs in absence of DNA replication, and is HIRA-and transcription-dependent. It is necessary for the shift from a somatic- to an oocyte-type of transcription after nuclear transfer. Conclusions This study demonstrates that the incorporation of histone H3.3 is an early and necessary step in the direct reprogramming of somatic cell nuclei by oocyte. It suggests that the incorporation of histone H3.3 is necessary during global changes in transcription that accompany changes in cell fate.
dc.languageEnglishen
dc.language.isoen
dc.titleHIRA dependent H3.3 deposition is required for transcriptional reprogramming following nuclear transfer to Xenopus oocytesen
dc.typeArticle
dc.date.updated2013-01-07T16:09:17Z
dc.description.versionRIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are.en
dc.rights.holderJerome Jullien et al.; licensee BioMed Central Ltd.
prism.publicationDate2012en
dcterms.dateAccepted2012-09-04en
rioxxterms.versionofrecord10.1186/1756-8935-5-17en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2012-10-29en
dc.contributor.orcidJullien, Jerome [0000-0002-7868-0021]
dc.contributor.orcidGurdon, John [0000-0002-5621-3799]
dc.identifier.eissn1756-8935
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (G1001690)
pubs.funder-project-idWellcome Trust (092096/Z/10/Z)


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record